The purpose of this phase II clinical trial is to determine the proportion of men with residual/recurrent clinically significant prostate cancer following the combination treatment of ADT and FT of the prostate in men with non-metastatic intermediate risk prostate cancer; defined as, men with a histopathologic diagnosis of Grade Group 2 & 3, with prostate specific antigen level <20 ng/mL. The gene discussed is KLK3; the disease is Familial prostate cancer.